射频消融对比立体定向体部放疗治疗复发性小肝癌:一项随机、开放标签、对照试验
本随机对照试验纳入166例复发性小肝癌(单病灶≤5 cm)患者,随机分入立体定向体部放疗(SBRT)组和射频消融(RFA)组各83例。中位随访约42.8和42.9个月时,SBRT的局部无进展生存(LPFS)显著优于RFA(HR 0.45,95%CI 0.24-0.87;P=0.014),而两组无进展生存、总生存及安全性相当。
要点
- SBRT组2年LPFS为92.7%,RFA组为75.8%,SBRT显著改善LPFS(HR 0.45,P=0.014)。
- 两组中位PFS分别为37.6个月和27.6个月(HR 0.76,P=0.190),无显著差异。
- 两组2年OS分别为97.6%和93.9%(HR 0.91,P=0.830),急性和晚期不良事件发生率相当。
核心结论
- 对于单发复发性小肝癌(≤5 cm)患者,SBRT较RFA获得更好的LPFS,尤其在≤2 cm的HCC中,而PFS、OS和安全性两组相当。
研究设计与样本
- 随机、开放标签、对照试验,2019年8月至2022年4月共纳入166例复发性小肝癌(单病灶≤5 cm)患者,随机分入SBRT组(n=83)和RFA组(n=83)。
- 主要终点为局部无进展生存(LPFS),次要终点为无进展生存(PFS)、总生存(OS)、局部控制率和安全性。
主要发现
- SBRT组和RFA组中位随访时间分别为42.8个月和42.9个月。
- SBRT组LPFS显著优于RFA组(HR 0.45,95%CI 0.24-0.87;P=0.014);2年LPFS率SBRT组为92.7%(95%CI 87.3-98.5),RFA组为75.8%(95%CI 67.2-85.7)。
- SBRT组和RFA组中位PFS分别为37.6个月(95%CI 26.0-49.2)和27.6个月(95%CI 20.3-34.8)(HR 0.76,95%CI 0.50-1.15;P=0.190)。
- SBRT组9例、RFA组10例患者随访期间死亡;2年OS率SBRT组为97.6%(95%CI 94.3-100.0),RFA组为93.9%(95%CI 88.9-99.2)(HR 0.91,95%CI 0.37-2.22;P=0.830)。
- 两组急性和晚期不良事件发生率相当(P=0.436和P=0.715)。
关键数值与推荐
- SBRT组2年LPFS率为92.7%(95%CI 87.3-98.5),RFA组为75.8%(95%CI 67.2-85.7)。
- SBRT组中位PFS为37.6个月(95%CI 26.0-49.2),RFA组为27.6个月(95%CI 20.3-34.8)。
- SBRT组2年OS率为97.6%(95%CI 94.3-100.0),RFA组为93.9%(95%CI 88.9-99.2)。
- LPFS的HR为0.45(95%CI 0.24-0.87;P=0.014),PFS的HR为0.76(95%CI 0.50-1.15;P=0.190),OS的HR为0.91(95%CI 0.37-2.22;P=0.830)。
临床怎么用
- 对于单发复发性小肝癌(≤5 cm)患者,SBRT在LPFS方面优于RFA,尤其在HCC≤2 cm时;PFS、OS和安全性两组相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC). METHODS: In this trial, patients with recurrent small HCC (single lesion ≤5 cm) were randomly assigned to receive either SBRT or RFA. The primary end point was local progression-free survival (LPFS), and secondary end points were progression-free survival (PFS), overall survival (OS), local control rate, and safety. RESULTS: Between August 2019 and April 2022, 166 patients were assigned to SBRT (n = 83) and RFA (n = 83) groups. After a median follow-up time of 42.8 and 42.9 months in the SBRT and RFA groups, respectively, SBRT demonstrated a significantly better LPFS than that of RFA (hazard ratio [HR], 0.45 [95% CI, 0.24 to 0.87]; P = .014). The 2-year LPFS rates were 92.7% (95% CI, 87.3 to 98.5) with SBRT and 75.8% (95% CI, 67.2 to 85.7) with RFA. The median PFS time of the SBRT and RFA groups was 37.6 (95% CI, 26.0 to 49.2) and 27.6 (95% CI, 20.3 to 34.8) months, respectively (HR, 0.76 [95% CI, 0.50 to 1.15]; P = .190). Nine patients in the SBRT group and 10 in the RFA group died during the follow-up. The 2-year OS rates were 97.6% (95% CI, 94.3 to 100.0) in the SBRT group and 93.9% (95% CI, 88.9 to 99.2) in the RFA group (HR, 0.91 [95% CI, 0.37 to 2.22]; P = .830). The incidences of both acute and late adverse events were comparable between the groups (P = .436 and P = .715, respectively). CONCLUSION: SBRT achieved better LPFS than that of RFA in patients with single recurrent HCC ≤5 cm, especially in HCC ≤2 cm, whereas PFS, OS, and safety were comparable between the two treatments.
引用
- Xi M, Yang Z, Hu L, et al. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial. J Clin Oncol. 2024. PMID: 39693584. doi:10.1200/JCO-24-01532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。